Two professionals, one in a lab coat, shake hands in a biotechnology lab setting with digital analytics screens in the background, symbolizing a strategic partnership involving NextCure.

#NXTC jumped 8% premarket after announcing a partnership with Simcere Zaiming to develop SIM0505, a novel antibody-drug conjugate targeting CDH6 in solid tumors. U.S. Phase 1 trial expected to begin in Q3 2025.
#NextCureInc
prismmarketview.com/nextcure-ral...